Androgenetic alopecia (AGA), colloquially known as male or female pattern baldness, is a hereditary condition characterized by progressive hair thinning and loss. It is the most common cause of hair loss, affecting both men and women. AGA results from a complex interplay of genetic and hormonal factors, particularly the influence of androgens like dihydrotestosterone (DHT) on susceptible hair follicles. The psychological impact of AGA can be profound, affecting self-esteem and quality of life. While not curable, various treatments, including topical minoxidil, oral finasteride, and hair transplantation, aim to slow progression or restore hair density (1)

Hair transplantation (HT) is a method of transferring hair follicles from a donor area to a recipient/bald area. The most commonly chosen donor site is the occipital region as the hair in this region is unaffected by AGA. When the hair in the occipital region is scanty or insufficient, facial hair and body hair may be used. The rationale for hair transplantation in AGA is donor dominance, i.e., the transplanted hair continues to be unaffected by the balding process even after relocation to the new site (2). Hair transplantation is a widely adopted solution for androgenetic alopecia, yet postoperative challenges persist, such as delayed growth and donor site scarring.

This research investigates the potential of oral minoxidil in enhancing post-transplantation outcomes. Recognizing the need for adjunctive therapies, we explore the rationale behind incorporating oral minoxidil, initially a vasodilator, and its impact on graft survival, growth acceleration, and overall patient satisfaction.